News | Magnetic Resonance Imaging (MRI) | May 29, 2025

Latest Swoop system software delivers a substantial increase in image quality for AI-powered portable MR brain imaging.


May 29, 2025 — Hyperfine, Inc., producer of the world’s first FDA-cleared AI-powered portable MRI system for the brain — the Swoop system — has announced FDA clearance of its next-generation software.

This tenth-generation release delivers a substantial increase in image quality for ultra-low-field MR imaging. Optive AI software enhances each stage of the imaging process   — from noise cancellation and image acquisition to reconstruction and post-processing. The result is brain images with greater clarity uniformity, and sharper anatomical detail. These advanced AI algorithms are applied across all sequences.

Earlier this year, Hyperfine released the software at select clinical sites where early users responded enthusiastically to the image quality improvements, with some reporting that image quality is approaching that of conventional 1.5 tesla MRI scanners. This feedback underscores the clarity and consistency of the new images that can enhance patient care.

“This software release marks the beginning of a transformative era for Hyperfine. The advanced AI algorithms integrated into our new software platform dramatically elevate image quality at ultra-low field strength, enabling more confident diagnoses at the point of care. We previewed Optive AI software at the recent American Society of Neuroradiology annual meeting and received outstanding feedback. It’s the strongest signal yet of where we’re headed—and how far AI-powered portable MRI imaging can go,” said Rafael O’Halloran, Hyperfine Vice President of Technology.

“Optive AI software is our tenth software release since initial FDA clearance and marks a critical inflection point in the evolution of Swoop® system technology—the first of two major technology milestones we have been looking forward to this year. The significant image quality enhancements enabled by Optive AI software will serve as a catalyst for our 2025 growth strategy, supporting expansion into new hospital sites of care and our entry into the neurology office market,” said Tom Teisseyre, Hyperfine Chief Operating Officer.

Hyperfine plans to initiate the rollout of Optive AI software to accounts in the third quarter of 2025.

For more information about the Swoop AI-powered portable MRI system, please visit hyperfine.io.


Related Content

News | Magnetic Resonance Imaging (MRI)

April 27 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Computed Tomography (CT)

April 23, 2026 — Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its ...

Time April 30, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | Contrast Agents

April 23, 2026 — On April 23, GE HealthCare announced the first patient has been dosed in the international, multi ...

Time April 23, 2026
arrow
News | Radiology Imaging

April 20, 2026 — Bracco Imaging has announced a strategic alliance with NYU Langone Health to advance innovation in ...

Time April 23, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Computed Tomography (CT)

April 2, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for True ...

Time April 03, 2026
arrow
News | Ultrasound Imaging

March 30, 2026 — Butterfly Network, Inc. has received clearance from the U.S. Food and Drug Administration (FDA) for a ...

Time April 01, 2026
arrow
Subscribe Now